Abstract | OBJECTIVE: METHODS: RESULTS: Twenty-nine of 150 tamoxifen-treated patients (19.3%) had ovarian cysts. Cysts were detected in 28 of 57 pre-menopausal women (49.1%) and 1 of 93 post-menopausal women (1.1%). Patients with ovarian cysts had higher serum E(2) levels compared with patients without cysts (24 versus 345 pg/ml; P < 0.001). Patients with ovarian cysts had <1 year amenorrhoea duration (P < 0.001) compared with the patients without cysts. Adjuvant standard chemotherapy did not have relationship between the development of ovarian cysts. Multivariant analysis showed that cyst development is related to high E(2) levels (P < 0.05). CONCLUSIONS: Patients still having a menstrual cycle during tamoxifen had high risk (58.33%) of developing ovarian cysts. We have described an association between pre-menopausal patients using tamoxifen with high E(2) level and ovarian cyst enlargement.
|
Authors | Jale Metindir, Sabahattin Aslan, Gülay Bilir |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 35
Issue 10
Pg. 607-11
(Oct 2005)
ISSN: 0368-2811 [Print] England |
PMID | 16254040
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Tamoxifen
- Estradiol
- Follicle Stimulating Hormone
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Amenorrhea
(etiology)
- Antineoplastic Agents, Hormonal
(adverse effects)
- Breast Neoplasms
(drug therapy, surgery)
- Estradiol
(blood)
- Female
- Follicle Stimulating Hormone
(blood)
- Humans
- Middle Aged
- Ovarian Cysts
(blood, chemically induced)
- Postmenopause
- Premenopause
- Retrospective Studies
- Tamoxifen
(adverse effects)
|